- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02609854
Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions
January 29, 2017 updated by: ZetrOZ, Inc.
ZetrOZ's Ultrasonic Diathermy device is intended for use as a portable and wearable medical device which, when applied to various areas of the body applies Low Intensity Therapeutic Ultrasound (LITUS) to deep tissues.
This device is FDA-cleared for pain reduction, treatment of muscle spasm and joint contracture, and increasing local circulation.
This study will look at the use of therapeutic ultrasound to relieve pain and reduce disability in subjects with chronic low back pain, a subset of which will have chronic low back pain due to a herniated disc, over an 8-week treatment period.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Dryden, New York, United States, 13053
- Medical Pain Consultants
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Osteopathic Medical Arts
-
-
Utah
-
Ogden, Utah, United States, 84408
- Weber State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Chronic low back pain, may be secondary to herniated nucleus pulposus (HNP) or other causes
- 18-60 years of age, inclusive
- Has Numeric Rating Scale (NRS) pain severity score of at least 4 for a minimum 5 days over the 1 week Baseline Period prior to being randomized to treatment
- Pain lasting >3 months
- Has MRI from within 2 months prior to Screening (If no recent MRI is available, then subject must agree to have MRI performed prior to randomization of treatment)
- If pain is secondary to HNP: MRI within the last 2 months demonstrating the presence of a herniated disc; herniated disc is laterally located and not centrally located; herniated disc is not sequestered
- Has the presence of radicular pain as assessed by a health care practitioner
- Is willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.
- Is maintained on a stable pain management regimen, which may include opioid and/or non-opioid analgesic medications, but must be willing to keep dosage(s) stable through the study period; any dose adjustments that the investigator feels are required during the study period must be discussed with the study sponsor; and the use of any medications must be documented in the subject's Medication Log.
- Be willing to discontinue any other interventional treatment modalities on the lower back during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).
Exclusion Criteria:
- Cannot successfully demonstrate the ability to put on and take off the device.
- Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.
- Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.
- Has arthritis, bone spurs, stenosis, fusions, or implants near the treatment area.
- Is pregnant.
- Is a prisoner.
- Is non-ambulatory (unable to walk).
- Has a pacemaker.
- Has a malignancy in the treatment area.
- Has an active infection, open sores, or wounds in the treatment area.
- Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.
- Has a known neuropathy (disease of the brain or spinal nerves).
- Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).
- Has peripheral artery disease.
- Has BMI ≥30
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sham Sustained Acoustic Medicine Device
Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
|
Inactive ultrasound device
|
|
Experimental: 3 MHz Sustained Acoustic Medicine Device
3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
|
Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Brief Pain Inventory-Short Form (BPI-SF): Pain Severity
Time Frame: Change from Baseline to Week 8
|
Change from Baseline to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
BPI-SF: Pain Interference
Time Frame: Change from Baseline to Week 8
|
Change from Baseline to Week 8
|
|
Oswestry Disability Index
Time Frame: Change from Baseline to Week 8
|
Change from Baseline to Week 8
|
|
Numeric Rating Scale: Pain on Flexion
Time Frame: Change from Baseline to Week 8
|
Change from Baseline to Week 8
|
|
Numeric Rating Scale: Pain on Extension
Time Frame: Change from Baseline to Week 8
|
Change from Baseline to Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
November 17, 2015
First Submitted That Met QC Criteria
November 17, 2015
First Posted (Estimate)
November 20, 2015
Study Record Updates
Last Update Posted (Estimate)
January 31, 2017
Last Update Submitted That Met QC Criteria
January 29, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intervertebral Disc Displacement
-
Jaseng Medical FoundationCompletedLumbar Intervertebral Disc Displacement | Cervical Intervertebral Disc DisplacementKorea, Republic of
-
BioAlpha Inc.CompletedIntervertebral Disk Degeneration | Intervertebral Disk DisplacementKorea, Republic of
-
OhioHealthNuTech Medical, IncTerminatedMusculoskeletal Diseases | Spinal Diseases | Bone Diseases | Spinal Stenosis | Spondylosis | Spondylolisthesis | Spondylolysis | Lumbar Degenerative Disc Disease | Intervertebral Disk Degeneration | Intervertebral Disk DisplacementUnited States
-
Saglik Bilimleri UniversitesiCompletedDisplacement of Intervertebral Disc Without MyelopathyTurkey
-
Seoul National University HospitalCompletedLumbar Herniated Intervertebral DiscKorea, Republic of
-
Seoul National University HospitalCompletedOssification of Posterior Longitudinal Ligament | Intervertebral Disk Degeneration | Intervertebral Disk DisplacementKorea, Republic of
-
Shin Poong Pharmaceutical Co. Ltd.CompletedTissue Adhesion, Surgery-Induced | Intervertebral Disc Disorder | Thoracic Intervertebral Disc Disorders | Thoracolumbar Intervertebral Disc Disorders | Lumbosacral Intervertebral Disc DisordersKorea, Republic of
-
Seoul National University HospitalCompletedCervical Disc DiseaseKorea, Republic of
-
Seikagaku CorporationCompletedLumbar Disc Disease | Intervertebral Disc DiseaseUnited States, Germany, Spain, Romania
-
Medipol UniversityCompletedLumbar Disc Herniation | Lumbar Disc DiseaseTurkey (Türkiye)
Clinical Trials on Sham Device
-
Medical University of South CarolinaCompletedUse of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)Upper Respiratory InfectionUnited States
-
Neurolief Ltd.Completed
-
Neurolief Ltd.Terminated
-
Queen Mary University of LondonBarts & The London NHS Trust; Homerton University HospitalRecruitingDystonia | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Parkinson's Disease and Parkinsonism | Vascular Parkinsonism | Orthostatic Tremor | Different Types of Tremor Including Essential TremorUnited Kingdom
-
Northwell HealthUniversity of OklahomaCompletedPremature Ventricular ContractionUnited States
-
The Hong Kong Polytechnic UniversityNot yet recruitingAMD - Age-Related Macular DegenerationChina
-
Neuroelectrics CorporationCompletedEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Icahn School of Medicine at Mount SinaiHumanity Neurotech Inc.CompletedCognitive Dysfunction | Post-Acute COVID-19 SyndromeUnited States
-
The Hong Kong Polytechnic UniversityCompletedPresbyopia | Asthenopia | Visual FatigueHong Kong
-
Thimble Bioelectronics, Inc.University of California, San FranciscoWithdrawn